5 recruiting, 4 completed, 2 not yet recruiting, 2 unknown. 15 Phase 2, 3 Phase 3, 1 Phase 1.
Follow Graves' Disease: new trials by email Literature Review of Graves' Disease trials Research Report on Graves' Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease BHV-1300 - Graves' Disease | Phase 2 / Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 356 | 2026-10-01 | 2026-10-28 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old Felzartamab, Placebo - Graves' Disease | Phase 2 | Recruiting | Biogen | 60 | 2026-07-30 | 2026-10-28 |
| Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease Experimental: YB-101, Placebo YB-101 - Graves' Disease | Phase 2 | Recruiting | Yarrow Bioscience, Inc. | 232 | 2026-06-10 | 2026-10-30 |
| A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) IMVT-1402 - Graves' Disease | Phase 2 | Enrolling by invitation | Immunovant Sciences GmbH | 372 | 2026-01-26 | 2026-09-29 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease Rilzabrutinib dose 1, Rilzabrutinib dose 2 - Graves' Disease | Phase 2 | Recruiting | Sanofi | 30 | 2025-09-02 | 2026-10-28 |
| Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease Ergocalciferol 50,000 IU, Methimazole - Graves Disease, Graves' Disease | Phase 2 | Active not recruiting | Northwell Health | 30 | 2025-08-25 | 2026-10-23 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 210 | 2025-06-19 | 2026-10-30 |
| A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease IMVT-1402, Placebo - Graves' Disease | Phase 2 | Recruiting | Immunovant Sciences GmbH | 240 | 2024-12-17 | 2026-08-25 |
| Graves' Disease Remission Study: MycoMeth Combo Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg - Graves' Disease | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Xiamen University | 205 | 2023-10-16 | 2024-02-28 |
| A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease CFZ533 - Graves' Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 15 | 2016-04-19 | 2021-01-05 |
| Role of the Microbiome in Graves' Orbitopathy LAB4 - Graves' Disease | Phase 1 / Phase 2 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 60 | 2015-02-01 | 2015-02-27 |
| Early Levothyroxine Post Radioactive Iodine Levothyroxine, Placebo - Graves' Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 61 | 2013-09-01 | 2019-10-29 |
| Radioactive Iodide Therapy for Pediatric Graves' Disease RAI treatment, ATD Group - Graves' Disease | Phase 2 | Completed | University of Florida | 19 | 2010-10-01 | 2017-11-06 |
| rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Recombinant human thyrotropin (Thyrogen) - Benign Nontoxic and Toxic Goiter, Graves' Disease | Phase 2 | Completed | Odense University Hospital | 110 | 2002-04-01 | 2010-12-28 |
Graves Disease (15) · Hyperthyroidism (7) · Graves Ophthalmopathy (1) · Hypothyroidism (1) · Neoplasms (1) · Patient Satisfaction (1)
Autoimmune Diseases (15) · Endocrine System Diseases (15) · Exophthalmos (15) · Eye Diseases (15) · Goiter (15) · Immune System Diseases (15) · Orbital Diseases (15) · Thyroid Diseases (15) · Hyperthyroidism (8) · Behavior (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Health Behavior (1) · Treatment Adherence and Compliance (1)
Methimazole (2) · Atorvastatin (1) · Ergocalciferols (1) · Mycophenolic Acid (1) · Thyroid Hormones (1) · Thyrotropin Alfa (1) · Thyroxine (1) · felzartamab (1) · iscalimab (1)
Immunovant Sciences GmbH (3) · Biogen (1) · Biohaven Therapeutics Ltd. (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Mayo Clinic (1) · Northwell Health (1) · Novartis Pharmaceuticals (1) · Odense University Hospital (1) · Region Skane (1) · Sanofi (1) · The First Affiliated Hospital of Xiamen University (1) · University of Florida (1) · Yarrow Bioscience, Inc. (1)
United States (9) · Italy (4) · United Kingdom (4) · Australia (3) · Georgia (3) · Germany (3) · Hungary (3) · Poland (3) · Spain (3) · Bulgaria (2) · Chile (2) · Czechia (2) · Greece (2) · Israel (2) · Latvia (2)
Fangsen Xiao, MD (1) · Mario Salvi, MD (1) · Marius Stan, MD (1) · Scott A Rivkees, MD (1) · Sharon Hyman, MD (1) · Tereza Planck (1) · Viveque Egsgaard Nielsen, MD (1)
PMID 16864757, PMID 18299459, PMID 26670972, PMID 27272078, PMID 27521067, PMID 27797318, PMID 29396246, PMID 30912336, PMID 31512728, PMID 32055040, PMID 32616746, PMID 32929476, PMID 34149627, PMID 34598995, PMID 35223896, PMID 35959915, PMID 36346684
2025 (2), 2015 (1), 2023 (1)